A pair of Cooley litigators left for Norton Rose Fulbright to beef up its patent litigation bench for pharma clients ahead of an expected rise in IP-related disputes.
Sanya Sukduang and Jonathan Davies plan to supplement Norton Rose Fulbright’s intellectual property practice with their experience in patent litigation for drugmakers—the “missing component” in the firm’s otherwise “full-service IP group,” Sukduang said in an interview.
Cooley, in an email statement, wished them well.
Norton Rose Fulbright allows the pair, who started in the firm’s DC office last week, to represent more life sciences clients because of the firm’s connections with pharma ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.